BRIEF—Chugai and Nippon Shinyaku launch Gazyva in Japan

Tokyo’s Chugai Pharmaceutical and Nippon Shinyaku have launched Gazyva (obinutuzumab), an anti-CD20 monoclonal antibody, as a treatment for follicular lymphoma in Japan.

Chugai, which is majority-owned by Swiss pharma giant Roche, obtained a manufacturing and marketing approval in early July.

The product is supported by strong efficacy data from the Phase lll GALLIUM study.

The firms say they will “work closely to make Gazyva contribute to the treatment of patients with CD20-positive follicular lymphoma as one of the standard therapies.”